Osteoblastogenesis and Adipogenesis Are Higher in Osteoarthritic than in Osteoporotic Bone Tissue

Archives of Medical Research

Volumn 42, Issue 5, 2011, Pages 392-397

  Dragojevič, Jana ^a   Logar, Darja Bitenc ^a   Komadina, Radko ^b   Marc, Janja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b General and Teaching Hospital Celje   (Slovenia)

Author keywords

Fracture; Gene expression; Osteoarthritis; Osteoporosis; PPAR ; RUNX2

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN; FATTY ACID BINDING PROTEIN 4; OSTEOCALCIN; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ADIPOGENESIS; AGED; ARTICLE; BONE DEVELOPMENT; DOWNSTREAM PROCESSING; FEMALE; GENE EXPRESSION; HIP ARTHROPLASTY; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOPOROSIS; TRANSCRIPTION INITIATION;

ADIPONECTIN; ADIPOSE TISSUE; AGED; BONE DENSITY; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; HUMANS; MALE; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOPOROSIS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80052763526     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.08.005     Document Type: Article

References (43)

1. Aspden R.M. Osteoarthritis: a problem of growth not decay?. Rheumatology (Oxford) 2008, 47:1452-1460.
2. Truong L.H., Kuliwaba J.S., Tsangari H., et al. Differential gene expression of bone anabolic factors and trabecular bone architectural changes in the proximal femoral shaft of primary hip osteoarthritis patients. Arthritis Res Ther 2006, 8:R188.
3. Dequeker J., Boonen S., Aerssens J., et al. Inverse relationship osteoarthritis-osteoporosis: what is the evidence? What are the consequences?. Br J Rheumatol 1996, 35:813-818.
4. Ducy P., Starbuck M., Priemel M., et al. A cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999, 13:1025-1036.
5. Nakashima K., Zhou X., Kunkel G., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
6. Nishio Y., Dong Y., Paris M., et al. Runx2-mediated regulation of the zinc finger osterix/sp7 gene. Gene 2006, 372:62-70.
7. Rosen E.D., Sarraf P., Troy A.E., et al. Ppar gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
8. Barak Y., Nelson M.C., Ong E.S., et al. Ppar gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
9. Hong J.H., Hwang E.S., McManus M.T., et al. Taz, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
10. Justesen J., Stenderup K., Ebbesen E.N., et al. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2001, 2:165-171.
11. Shen W., Chen J., Punyanitya M., et al. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in caucasian women. Osteoporos Int 2007, 18:641-647.
12. Ali A., Weinstein R., Stewart S., et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
13. Rzonca S.O., Suva L.J., Gaddy D., et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
14. Akune T., Ohba S., Kamekura S., et al. Ppargamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
15. Cock T.A., Back J., Elefteriou F., et al. Enhanced bone formation in lipodystrophic ppargamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004, 5:1007-1012.
16. Jiang Y., Mishima H., Sakai S., et al. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders. J Orthop Res 2008, 26:910-917.
17. Zhang Z.M., Jiang L.S., Jiang S.D., et al. Osteogenic potential and responsiveness to leptin of mesenchymal stem cells between postmenopausal women with osteoarthritis and osteoporosis. J Orthop Res 2009, 27:1067-1073.
18. Fajas L., Auboeuf D., Raspé E., et al. The organization, promoter analysis, and expression of the human ppargamma gene. J Biol Chem 1997, 272:18779-18789.
19. Vidal-Puig A., Considine R., Jimenez-Liñan M., et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997, 99:2416-2422.
20. Mukherjee R., Jow L., Croston G.E., et al. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (ppar) isoforms ppargamma2 versus ppargamma1 and activation with retinoid x receptor agonists and antagonists. J Biol Chem 1997, 272:8071-8076.
21. Ducy P., Zhang R., Geoffroy V., et al. Osf2/cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
22. Seibel M.J. Biochemical markers of bone turnover: I: Biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
23. Iwaki M., Matsuda M., Maeda N., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
24. Heid H.W., Moll R., Schwetlick I., et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998, 294:309-321.
25. Yoshida K., Shimizugawa T., Ono M., et al. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 2002, 43:1770-1772.
26. Jiang L.S., Zhang Z.M., Jiang S.D., et al. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. J Bone Miner Res 2008, 23:475-483.
27. Plumb M.S., Aspden R.M. High levels of fat and (n-6) fatty acids in cancellous bone in osteoarthritis. Lipids Health Dis 2004, 3:12.
28. Walczak R., Tontonoz P. Pparadigms and pparadoxes: expanding roles for ppargamma in the control of lipid metabolism. J Lipid Res 2002, 43:177-186.
29. Watters J.W., Cheng C., Pickarski M., et al. Inverse relationship between matrix remodeling and lipid metabolism during osteoarthritis progression in the str/ort mouse. Arthritis Rheum 2007, 56:2999-3009.
30. Knowles H.J., Cleton-Jansen A.M., Korsching E., et al. Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J 2010, 24:4648-4659.
31. Trost Z., Trebse R., Prezelj J., et al. A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts. Bone 2010, 46:72-80.
32. Targett-Adams P., McElwee M.J., Ehrenborg E., et al. A ppar response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta 2005, 1728:95-104.
33. Dalen K.T., Schoonjans K., Ulven S.M., et al. Adipose tissue expression of the lipid droplet-associating proteins s3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004, 53:1243-1252.
34. Mandard S., Zandbergen F., Tan N.S., et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (fiaf/pgar/angptl4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 2004, 279:34411-34420.
35. Ge H., Cha J., Gopal H., et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res 2005, 46:1484-1490.
36. Yoon J.C., Chickering T.W., Rosen E.D., et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000, 20:5343-5349.
37. Giaginis C., Tsantili-Kakoulidou A., Theocharis S. Peroxisome proliferator-activated receptors (ppars) in the control of bone metabolism. Fundam Clin Pharmacol 2007, 21:231-244.
38. Hopwood B., Tsykin A., Findlay D.M., et al. Gene expression profile of the bone microenvironment in human fragility fracture bone. Bone 2009, 44:87-101.
39. Fink T., Abildtrup L., Fogd K., et al. Induction of adipocyte-like phenotype in human mesenchymal stem cells by hypoxia. Stem Cells 2004, 22:1346-1355.
40. Park J.H., Park B.H., Kim H.K., et al. Hypoxia decreases runx2/cbfa1 expression in human osteoblast-like cells. Mol Cell Endocrinol 2002, 192:197-203.
41. Griffith J.F., Yeung D.K., Tsang P.H., et al. Compromised bone marrow perfusion in osteoporosis. J Bone Miner Res 2008, 23:1068-1075.
42. Ross S.R., Graves R.A., Greenstein A., et al. A fat-specific enhancer is the primary determinant of gene expression for adipocyte p2 in vivo. Proc Natl Acad Sci USA 1990, 87:9590-9594.
43. Karaoz E., Okcu A., Gacar G., et al. A comprehensive characterization study of human bone marrow mscs with an emphasis on molecular and ultrastructural properties. J Cell Physiol 2011, 226:1367-1382.